The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Role of OATP Transporters in the Disposition of Drugs
Abstract
During recent years, it has become increasingly recognized that drug transporters play important roles in drug absorption and disposition. Organic anion transporting polypeptides (OATPs) are membrane transporters critically involved in the cellular uptake of drugs in tissues important for pharmacokinetics, such as the intestine, liver and kidneys. Recent advances in the pharmacogenomics of OATP1B1 have revealed that OATP transporters can play important roles in explaining interindividual variability in drug pharmacokinetics, and thus contribute to interindividual as well as interethnic variability in drug response. This article will provide an up-to-date review of human OATPs and their substrates, and a current compilation of their DNA sequence variations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hagenbuch, B., & Meier, P. J. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1168-y · Cited by 1,019
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Self-citationPharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Self-citationKullak-Ublick, G. A., Ismair, M. G., Stieger, B., Landmann, L., Huber, R., Pizzagalli, F., Fattinger, K., Meier, P. J., & Hagenbuch, B. (2001) · Gastroenterology · doi:10.1053/gast.2001.21176 · Cited by 723
Tamai, I., Nezu, J.-I., Uchino, H., Sai, Y., Oku, A., Shimane, M., & Tsuji, A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2922 · Cited by 642
A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 641
Tirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 626
König, J., Cui, Y., Nies, A. T., & Keppler, D. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.1.g156 · Cited by 620
Ho, R. H., Tirona, R. G., Leake, B. F., Glaeser, H., Lee, W., Lemke, C. J., Wang, Y., & Kim, R. B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.034 · Cited by 611
Dresser, G. K., Bailey, D. G., Leake, B. F., Schwarz, U. I., Dawson, P. A., Freeman, D. J., & Kim, R. B. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121152 · Cited by 606
OATP and P-Glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine
Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., & Kim, R. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15235-x · Cited by 597
Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1
Abe, T., Kakyo, M., Tokui, T., Nakagomi, R., Nishio, T., Nakai, D., Nomura, H., Unno, M., Suzuki, M., Naitoh, T., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17159 · Cited by 543
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
Transporters and drug therapy: Implications for drug disposition and disease
HO, R., & KIM, R. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.05.011 · Cited by 502
Transporters as a determinant of drug clearance and tissue distribution
Shitara, Y., Horie, T., & Sugiyama, Y. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.12.003 · Cited by 496
LEE, E., RYAN, S., BIRMINGHAM, B., ZALIKOWSKI, J., MARCH, R., AMBROSE, H., MOORE, R., LEE, C., CHEN, Y., & SCHNECK, D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.013 · Cited by 480
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230416.82349.90 · Cited by 470
Self-citationContribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068056 · Cited by 443
Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin
Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Niemi, M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100220 · Cited by 432
Self-citationKullak-Ublick, G. A., Hagenbuch, B., Stieger, B., Schteingart, C. D., Hofmann, A. F., Wolkoff, A. W., & Meier, P. J. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90588-x · Cited by 428
Niemi, M., Schaeffeler, E., Lang, T., Fromm, M. F., Neuvonen, M., Kyrklund, C., Backman, J. T., Kerb, R., Schwab, M., Neuvonen, P. J., et al. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114750.08559.32 · Cited by 418
Self-citationKobayashi, D., Nozawa, T., Imai, K., Nezu, J.-I., Tsuji, A., & Tamai, I. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051300 · Cited by 416
SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409
Self-citationShitara, Y., Hirano, M., Sato, H., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068536 · Cited by 407
Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans
Glaeser, H., Bailey, D. G., Dresser, G. K., Gregor, J. C., Schwarz, U. I., McGrath, J. S., Jolicoeur, E., Lee, W., Leake, B. F., Tirona, R. G., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100056 · Cited by 407
Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M., & Chiba, K. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000170913.73780.5f · Cited by 379
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver
Vavricka, S. R., Van Montfoort, J., Ha, H. R., Meier, P. J., & Fattinger, K. (2002) · Hepatology · doi:10.1053/jhep.2002.34133 · Cited by 373
Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2)
Lee, W., Glaeser, H., Smith, L. H., Roberts, R. L., Moeckel, G. W., Gervasini, G., Leake, B. F., & Kim, R. B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411092200 · Cited by 365
NIEMI, M., BACKMAN, J., KAJOSAARI, L., LEATHART, J., NEUVONEN, M., DALY, A., EICHELBAUM, M., KIVISTO, K., & NEUVONEN, P. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.018 · Cited by 360
Self-citationPharmacogenomics of human OATP transporters
König, J., Seithel, A., Gradhand, U., & Fromm, M. F. (2006) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-006-0040-y · Cited by 357
Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human
Nozawa, T., Imai, K., Nezu, J.-I., Tsuji, A., & Tamai, I. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060194 · Cited by 351
Abe, T., Unno, M., Onogawa, T., Tokui, T., Kondo, T. N., Nakagomi, R., Adachi, H., Fujiwara, K., Okabe, M., Suzuki, T., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.24804 · Cited by 345
Shitara, Y., Itoh, T., Sato, H., Li, A. P., & Sugiyama, Y. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041921 · Cited by 340
Gemfibrozil greatly increases plasma concentrations of cerivastatin
Backman, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128469 · Cited by 336
SIMONSON, S. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.010 · Cited by 330
Ogilvie, B. W., Zhang, D., Li, W., Rodrigues, A. D., Gipson, A. E., Holsapple, J., Toren, P., & Parkinson, A. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007633 · Cited by 330
Lau, Y. Y., Huang, Y., Frassetto, L., & Benet, L. Z. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100038 · Cited by 327
Tirona, R. G., Leake, B. F., Wolkoff, A. W., & Kim, R. B. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.043026 · Cited by 324
Pizzagalli, F., Hagenbuch, B., Stieger, B., Klenk, U., Folkers, G., & Meier, P. J. (2002) · Molecular Endocrinology · doi:10.1210/me.2001-0309 · Cited by 320
Nozawa, T., Nakajima, M., Tamai, I., Noda, K., Nezu, J.-I., Sai, Y., Tsuji, A., & Yokoi, T. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.2.804 · Cited by 318
Nozawa, T., Minami, H., Sugiura, S., Tsuji, A., & Tamai, I. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001909 · Cited by 316
Jigorel, E., Le Vee, M., Boursier-Neyret, C., Parmentier, Y., & Fardel, O. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.010033 · Cited by 315
DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009290 · Cited by 302
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
Mwinyi, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.016 · Cited by 293
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
Schneck, D. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.014 · Cited by 292
Mikkaichi, T., Suzuki, T., Onogawa, T., Tanemoto, M., Mizutamari, H., Okada, M., Chaki, T., Masuda, S., Tokui, T., Eto, N., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0304987101 · Cited by 289
Bailey, D. G., Dresser, G. K., Leake, B. F., & Kim, R. B. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100104 · Cited by 287
Niemi, M., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2003) · Diabetologia · doi:10.1007/s00125-003-1034-7 · Cited by 284
Self-citationPlasma concentrations of active simvastatin acid are increased by gemfibrozil
Backman, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.108507 · Cited by 264
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
NIEMI, M., PASANEN, M., & NEUVONEN, P. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.06.010 · Cited by 250
Self-citationLu, R., Kanai, N., Bao, Y., & Schuster, V. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118897 · Cited by 240
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel
Smith, N. F., Acharya, M. R., Desai, N., Figg, II, & Sparreboom, A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.8.1867 · Cited by 234
CITRUS JUICES INHIBIT THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-B
Satoh, H., Yamashita, F., Tsujimoto, M., Murakami, H., Koyabu, N., Ohtani, H., & Sawada, Y. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002337 · Cited by 225
Regional Distribution of Solute Carrier mRNA Expression Along the Human Intestinal Tract
Meier, Y., Eloranta, J. J., Darimont, J., Ismair, M. G., Hiller, C., Fried, M., Kullak-Ublick, G. A., & Vavricka, S. R. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013342 · Cited by 223
Implications of genetic polymorphisms in drug transporters for pharmacotherapy
Kerb, R. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.06.051 · Cited by 219
GRUBE, M., KOCK, K., OSWALD, S., DRABER, K., MEISSNER, K., ECKEL, L., BOHM, M., FELIX, S., VOGELGESANG, S., & JEDLITSCHKY, G. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.010 · Cited by 215
Seithel, A., Eberl, S., Singer, K., Auge, D., Heinkele, G., Wolf, N. B., Dörje, F., Fromm, M. F., & König, J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.014407 · Cited by 207
Cyclosporine markedly raises the plasma concentrations of repaglinide
KAJOSAARI, L., NIEMI, M., NEUVONEN, M., LAITILA, J., NEUVONEN, P., & BACKMAN, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.005 · Cited by 207
Self-citationYamashiro, W., Maeda, K., Hirouchi, M., Adachi, Y., Hu, Z., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008938 · Cited by 202
MAEDA, K., IEIRI, I., YASUDA, K., FUJINO, A., FUJIWARA, H., OTSUBO, K., HIRANO, M., WATANABE, T., KITAMURA, Y., & KUSUHARA, H. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.01.011 · Cited by 200
Human Hepatobiliary Transport of Organic Anions Analyzed by Quadruple-Transfected Cells
Kopplow, K., Letschert, K., König, J., Walter, B., & Keppler, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014605 · Cited by 197
Kyrklund, C., Backman, J. T., Kivistö, K. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115542 · Cited by 191
Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes
Wang, J.-S., Neuvonen, M., Wen, X., Backman, J. T., & Neuvonen, P. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1352 · Cited by 189
Letschert, K., Keppler, D., & König, J. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114744.08559.92 · Cited by 187
Fujiwara, K., Adachi, H., Nishio, T., Unno, M., Tokui, T., Okabe, M., Onogawa, T., Suzuki, T., Asano, N., Tanemoto, M., et al. (2001) · Endocrinology · doi:10.1210/endo.142.5.8115 · Cited by 187
Dresser, G. K., Kim, R. B., & Bailey, D. G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.10.005 · Cited by 186
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone
Niemi, M., Backman, J. T., Granfors, M., Laitila, J., Neuvonen, M., & Neuvonen, P. J. (2003) · Diabetologia · doi:10.1007/s00125-003-1181-x · Cited by 186
Self-citationShimizu, M., Fuse, K., Okudaira, K., Nishigaki, R., Maeda, K., Kusuhara, H., & Sugiyama, Y. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004622 · Cited by 183
Chu, X.-Y., Bleasby, K., Yabut, J., Cai, X., Chan, G. H., Hafey, M. J., Xu, S., Bergman, A. J., Braun, M. P., Dean, D. C., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.116517 · Cited by 179
Chen, Z.-S., Kawabe, T., Ono, M., Aoki, S., Sumizawa, T., Furukawa, T., Uchiumi, T., Wada, M., Kuwano, M., & Akiyama, S.-I. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.6.1219 · Cited by 178
Ishiguro, N., Maeda, K., Kishimoto, W., Saito, A., Harada, A., Ebner, T., Roth, W., Igarashi, T., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.009175 · Cited by 178
Effect of () variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers
CHUNG, J., CHO, J., YU, K., KIM, J., OH, D., JUNG, H., LIM, K., MOON, K., SHIN, S., & JANG, I. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.003 · Cited by 170
Meier‐Abt, F., Mokrab, Y., & Mizuguchi, K. (2006) · The Journal of Membrane Biology · doi:10.1007/s00232-005-7004-x · Cited by 167
Tamai, I., & Safa, A. R. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)46252-1 · Cited by 166
Olbricht, C., Wanner, C., Eisenhauer, T., Kliem, V., Doll, R., Boddaert, M., O'Grady, P., Krekler, M., Mangold, B., & Christians, U. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90034-5 · Cited by 165
Huber, R. D., Gao, B., Sidler Pfändler, M.-A., Zhang-Fu, W., Leuthold, S., Hagenbuch, B., Folkers, G., Meier, P. J., & Stieger, B. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00597.2005 · Cited by 164
Smith, N. F., Marsh, S., Scott-Horton, T. J., Hamada, A., Mielke, S., Mross, K., Figg, W. D., Verweij, J., McLeod, H. L., & Sparreboom, A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100011 · Cited by 162
MUCK, W., MAI, I., FRITSCHE, L., OCHMANN, K., ROHDE, G., UNGER, S., JOHNE, A., BAUER, S., BUDDE, K., & ROOTS, I. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70104-9 · Cited by 158
Backman, J. T., Luurila, H., Neuvonen, M., & Neuvonen, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.04.007 · Cited by 156
Tachibana-Iimori, R., Tabara, Y., Kusuhara, H., Kohara, K., Kawamoto, R., Nakura, J., Tokunaga, K., Kondo, I., Sugiyama, Y., & Miki, T. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.375 · Cited by 153
Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus
Lemahieu, W. P. D., Hermann, M., Åsberg, A., Verbeke, K., Holdaas, H., Vanrenterghem, Y. F. C., & Maes, B. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01005.x · Cited by 149
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination
Smith, N. F., Figg, W. D., & Sparreboom, A. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.3.429 · Cited by 148
Iwai, M., Suzuki, H., Ieiri, I., Otsubo, K., & Sugiyama, Y. (2004) · Pharmacogenetics · doi:10.1097/00008571-200411000-00006 · Cited by 147
Campbell, S. D., de Morais, S. M., & Xu, J. J. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2004.08.008 · Cited by 144
Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol
Lilja, J. J., Backman, J. T., Laitila, J., Luurila, H., & Neuvonen, P. J. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.26 · Cited by 142
Michalski, C. W., Cui, Y., Nies, A. T., Nussler, A. K., Neuhaus, P., Zanger, U. M., Klein, K., Eichelbaum, M. F., KEPPLER, D. O. R., & König, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207735200 · Cited by 140
Árnadóttir, M., Eriksson, L.-O., Thysell, H., & Karkas, J. D. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000187521 · Cited by 137
Niemi, M., Kivistö, K. T., Hofmann, U., Schwab, M. G., Eichelbaum, M. F., & Fromm, M. F. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02354.x · Cited by 135
Self-citationIchimaru, N., Takahara, S., Kokado, Y., Wang, J. D., Hatori, M., Kameoka, H., Inoue, T., & Okuyama, A. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00438-5 · Cited by 130
Åsberg, A., Hartmann, A., Fjeldså, E., Bergan, S., & Holdaas, H. (2001) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2001.10415.x · Cited by 127
Niemi, M., Neuvonen, P. J., Hofmann, U., Backman, J. T., Schwab, M. G., Lütjohann, D., von Bergmann, K., Eichelbaum, M. F., & Kivistö, K. T. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200505000-00005 · Cited by 125
Self-citationPharmacogenomics of the OATP and OAT Families
Marzolini, C., Tirona, R. G., & Kim, R. B. (2004) · Pharmacogenomics · doi:10.1517/phgs.5.3.273.29831 · Cited by 124
Nozawa, T., Sugiura, S., Nakajima, M., Goto, A., Yokoi, T., Nezu, J., Tsuji, A., & Tamai, I. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.3.291 · Cited by 121
Pasanen, M. K., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0123-1 · Cited by 119
Self-citationMahagita, C., Grassl, S. M., Piyachaturawat, P., & Ballatori, N. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00075.2007 · Cited by 119
Regazzi, M. B., Iacona, I., Campana, C., Raddato, V., Lesi, C., Perani, G., Gavazzi, A., & Viganò, M. (1993) · PubMed · Cited by 114
HEPATIC UPTAKE OF THE NOVEL ANTIFUNGAL AGENT CASPOFUNGIN
Sandhu, P., Lee, W., Xu, X., Leake, B. F., Yamazaki, M., Stone, J. A., Lin, J. H., Pearson, P. G., & Kim, R. B. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003244 · Cited by 109
Igel, M., ARNOLD, K., Niemi, M., Hofmann, U., Schwab, M. G., Lütjohann, D., VONBERGMANN, K., Eichelbaum, M. F., & Kivistö, K. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.01.010 · Cited by 108
Self-citationSu, Y., Zhang, X., & Sinko, P. J. (2003) · Molecular Pharmaceutics · doi:10.1021/mp0340136 · Cited by 108
Fujino, H., Saito, T., Ogawa, S.-I., & Kojima, J. (2005) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.57.10.0009 · Cited by 104
Liu, L., Cui, Y., Chung, A. Y., Shitara, Y., Sugiyama, Y., KEPPLER, D. O. R., & Pang, K. S. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103390 · Cited by 103
Nakagomi, R., Nakai, D., Kawai, K., Yoshigae, Y., Tokui, T., Abe, T., & Ikeda, T. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008888 · Cited by 100
Katz, D. A., Carr, R. A., GRIMM, D., Xiong, H., Holley-Shanks, R. R., MUELLER, T., Leake, B. F., WANG, Q., Han, L., & WANG, P. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.11.003 · Cited by 99
Molecular characterization of human and rat organic anion transporter OATP-D
Adachi, H., Suzuki, T., Abe, M., Asano, N., Mizutamari, H., Tanemoto, M., Nishio, T., Onogawa, T., Toyohara, T., Kasai, S., et al. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00402.2002 · Cited by 98
Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A
Binet, I., Wallnöfer, A., Weber, C., Jones, R. D., & Thiel, G. T. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00838.x · Cited by 97
van Montfoort, J. E., Müller, M. M., Groothuis, G. M. M., Meijer, D. K. F., Koepsell, H., & Meier, P. J. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29357-5 · Cited by 94
Hedman, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.011 · Cited by 93
Treiber, A., Schneiter, R., Delahaye, S., & Clozel, M. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.061614 · Cited by 83
Steckelbroeck, S., Nassen, A., Ugele, B., Ludwig, M. Z., Watzka, M., Reissinger, A., Clusmann, H., Lütjohann, D., Siekmann, L., Klingmüller, D., et al. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2004.02336.x · Cited by 82
Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide
Lilja, J. J., Niemi, M., Fredrikson, H., & Neuvonen, P. J. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02836.x · Cited by 79
Self-citationPark, J., Siekmeier, R., Lattke, P., Merz, M., Mix, C., Schuiler, S., & Jaroß, W. (2001) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840100600404 · Cited by 78
Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects
Kyrklund, C., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01972.x · Cited by 77
Inhibitory and Inductive Effects of Rifampin on the Pharmacokinetics of Bosentan in Healthy Subjects
van Giersbergen, P. L. M., Treiber, A., Schneiter, R., Dietrich, H., & Dingemanse, J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100075 · Cited by 76
Fox, R. I., Morgan, S., Smith, H. T., Robbins, B. A., Choc, M. G., & Baggott, J. E. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg277 · Cited by 52
OATP-C(OATP01B1)*15 is associated with statin-induced myopathy in hypercholesterolemic patients
Morimoto, K., Ueda, S., Seki, N., IGAWA, Y., KAMEYAMA, Y., Shimizu, A., Oishi, T., Hosokawa, M., Iesato, K., & Mori, S. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.11.081 · Cited by 25
Cited by
Impact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
Self-citationNiemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 633
Self-citationPharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 457
ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
Keskitalo, J. E., Zolk, O., Fromm, M. F., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.79 · Cited by 416
Self-citationThe mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group
Koziolek, M., Alcaro, S., Augustijns, P., Basit, A. W., Grimm, M., Hens, B., Hoad, C. L., Jedamzik, P., Madla, C. M., Maliepaard, M., et al. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.003 · Cited by 385
Metadata
- Authors
- Niemi, M.
- Venue
- Pharmacogenomics
- Publisher
- Informa UK Limited
- Published
- 2007-07
- Volume
- 8
- Issue
- 7
- Pages
- 787-802
- ISSN
- 1462-2416 (ISSN-L)
- 1744-8042
- OpenAlex
- W2115151001
- Cited by
- 266
- References
- 115
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.